Compare AbbVie Inc (ABBV) vs Elastic NV (ESTC) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

Elastic (ESTC) trades at $58.54, up 0.86% with neutral technical signals. The company shows strong profitability metrics including 76% gross margins and 21% net income margin projected for 2026, though 2025 results showed a net loss. Recent earnings beats and positive analyst sentiment (67% buy ratings) support the stock, with a $72.80 consensus price target representing 24% upside potential.

ESTC presents a growth opportunity with improving financials and market leadership in search AI, though risks include ongoing legal investigations and competitive pressures. The stock's current valuation appears reasonable relative to growth prospects, with technical indicators suggesting consolidation near key support at $57.